Study of Early Versus Standard Treatment for Relapse in Multiple Myeloma Patients After First Line Therapy with Stem Cell Transplant
Led by Oslo University Hospital · Updated on 2025-03-20
176
Participants Needed
13
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether treating minimal residual disease MRD relapse earlier, after first line treatment for multiple myeloma, can prolong progression-free survival and overall survival compared to treating relapse at progressive disease. This study focuses on patients who become MRD negative after standard first line treatment including autologous stem cell transplantation, aiming to form a uniform group for comparison. The trial is conducted in phases II and III to assess these outcomes over many years.
Participants with newly diagnosed multiple myeloma eligible for high-dose therapy will first receive standard Norwegian care bortezomib, lenalidomide, and dexamethasone in 21-day cycles, with four cycles before and after transplant. After induction, patients undergo single or tandem autologous stem cell transplant ASCT based on response and toxicity. Those achieving MRD negativity post consolidation will be randomly assigned to start second-line treatment either at MRD relapse arm A or at progressive disease arm B. Both groups receive the same 28-day cycle treatment of carfilzomib, dexamethasone, and daratumumab until progression, unacceptable side effects, or withdrawal.
During the study, patients will have regular MRD assessments every four months in arm A and standard follow-up in arm B, with additional MRD checks scheduled at specific timepoints during second-line treatment. Researchers will measure progression-free survival, overall survival, MRD negativity rates, time to next treatment, and quality of life over 10 to 11 years. Participants will be closely monitored for safety and treatment response throughout their participation, which can last many years depending on outcomes.
CONDITIONS
Brief Title
The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study
Research Team
A
Anne-Marie Rasmussen, PhD
A
Anna Lysen, MSC
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Newly diagnosed multiple myeloma patients eligible for high-dose therapy and autologous stem cell transplant
Age between 18 and 75 years at informed consent
Measurable disease as defined by serum monoclonal paraprotein > 10 g/L or specific light chain criteria
Voluntary written informed consent
ECOG performance status of 0, 1, or 2 (3 if due to myeloma)
Willing and able to follow study visit schedule and protocol
Female of childbearing potential with negative serum pregnancy test within 7 days before inclusion
Use of effective contraception by sexually active females and males during and for 28 days after study drug
MRD negative status after first line therapy measured by Euroflow NGF
Received first line treatment within part 1 of the study
ECOG performance status 0, 1, or 2 at study entry
You will not qualify if you...
More than one cycle of induction treatment received for multiple myeloma
Ongoing or active systemic infection, active hepatitis B or C, or known HIV positive
Medical or psychiatric conditions incompatible with high-dose therapy and autologous stem cell transplant or reducing study compliance
Active malignancy with lower life expectancy than myeloma
Positive serum pregnancy test during screening
Lactating female unwilling to stop before treatment
Known allergy to study medications or their components
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
First Line Treatment
Duration - Approximately 8 cycles of 21 days each plus transplant period
Participants receive standard first line treatment with bortezomib, lenalidomide, and dexamethasone for induction, followed by autologous stem cell transplant(s) and consolidation therapy.
Multiple visits during 4 induction and 4 consolidation cycles plus transplant visits
MRD Assessment and Randomization
Duration - 30 to 45 days post consolidation
Participants who achieve MRD negative complete response after first line treatment are randomly assigned to one of two follow-up arms for monitoring and second line treatment.
1 visit (in-person) for MRD assessment and randomization
Follow-up and Second Line Treatment - Arm A
Duration - Continues until disease progression, unacceptable side effects, or withdrawal
Participants are monitored with MRD assessments every 4 months and start second line treatment with carfilzomib, dexamethasone, and daratumumab at loss of MRD negative complete response.
MRD assessments every 4 months; treatment cycles every 28 days
Follow-up and Second Line Treatment - Arm B
Duration - Continues until disease progression, unacceptable side effects, or withdrawal
Participants are monitored with standard criteria and start second line treatment with carfilzomib, dexamethasone, and daratumumab at progressive disease.
Standard clinical visits; MRD assessments if complete response is achieved, starting after 6 months of treatment
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Evaluating 18F-Fluciclovine PETCT Imaging for Multiple Myeloma Detection and Monitoring
Evaluating 68Ga-BCMA PETCT Imaging for Detecting BCMA in Multiple Myeloma Patients in a Multicenter Study
Italian National Registry to Monitor Diagnosis and Treatment of Multiple Myeloma
A Physician and Patient-Powered Cohort Study
Evaluating BCMA-Targeted Prime CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma and Plasma Cell Disease
Phase 1 Study of Subcutaneous TQB2934 Injection for Treating Malignant Plasma Cell Tumors Including Multiple Myeloma
Study of Allogeneic CD19 and BCMA CAR-T Cell Therapy for Adults with Relapsed or Refractory B-cell or Plasma Cell Tumors
Early Phase 1 Trial to Assess Safety and Effectiveness of RN1101 Treatment
Phase I Open-Label Study of SHR-5421 Injection Evaluating Safety and Preliminary Effects in Patients With Multiple Myeloma
Phase I Study of SHR-9539 Injection to Evaluate Safety and Effectiveness in Adults With Multiple Myeloma
Phase 1 Study of TQB2029 Injection to Test Safety and Effects in Adults With Multiple Myeloma
Evaluating Safety and Effectiveness of LVIVO-TaVec200 in Adults with Relapsed or Refractory Multiple Myeloma
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Optimizing lenalidomide therapy in renal impairment: analysis of renal response in the prospective REMNANT study in transplant-eligible newly diagnosed multiple myeloma.
Frida Bugge Askeland, Vilhelm Hauge Bugge, Anne-Marie Rasmussen...